GLP1R and chronic kidney disease: Conversely, in a young person with high risk of CKD progression and CVD risk despite optimum Tier 3 management, BP control should be tightened, the dose of RAS blocking drug maximised and GLP‐1 RA added to afford further protection to the kidney.